Fosun Pharma subsidiary secures funding, launches incentive program

Shanghai Fosun Pharmaceutical Group announced that its controlled subsidiary, Fosun Cario, will receive a staged investment of CNY 60,000万元 from Shenzhen Biomedical Industry Fund for A-round financing, increasing its registered capital by CNY 52,443.7452万元. This capital increase, along with a co-investment of CNY 352.50万元 by 14 participants, including Fosun Cario's management, into CNY 308.1070万元 of new registered capital, constitutes connected transactions due to overlapping board and management roles.

Concurrently, Fosun Cario is implementing an equity incentive plan, adopted on October 17, 2025, to attract and retain key talent. The plan will issue up to CNY 9,321.9893万元 of incentive equity in three tranches, with the first tranche valuing CNY 7,618.4870万元. This initiative aims to foster long-term growth and enhance the core team's motivation.

In a related development, Fosun Pharma also announced that HLX43, an antibody-drug conjugate for thymic epithelial tumors, has received Orphan-Drug Designation from the US FDA. This designation offers benefits such as tax credits for clinical trial costs and a seven-year market exclusivity period, bolstering HLX43's development and commercialization prospects in the US.